Effect of AZD1152 on the proliferation of MOLM13 cells in a murine xenograft model. MOLM13 cells were injected bilaterally subcutaneously into BALB/c nude mice, forming 2 tumors/mouse. After MOLM13 cells formed palpable tumors, mice were randomized into 2 groups (n=5) and treatment was initiated. AZD1152 (25 mg/kg per mouse) were administered to mice by intraperitoneal injection 4 times a week for 2 weeks. Control mice (n=5) were given control diluent. Tumor volumes were measured every week. Each point represents the mean ± SD of 10 tumors. (B) Tumor weights at autopsy. After 2 weeks of treatment, tumors were removed and weighed. Results represent mean ± SD of tumor weights. Statistical significance was determined by Mann-Whitney U test. Bars indicate SD. (C) Body weight of mice was measured twice a week during treatment. (D) Hematoxylin-eosin staining. Stained sections were examined and photographed with an Olympus BX50 (Olympus, Tokyo, Japan). MOLM13 tumors from mice treated with AZD1152 (right panel) showed extensive tumor necrosis with phagocytes (original magnification × 200). Diluent control displayed sheets of leukemia cells (left panel).